Targeting the Bcl-2 family in cancer therapy

被引：60

作者：

Papadopoulos, Kyriakos

机构：

[1] Univ Texas, Hlth Sci Ctr, Canc Therapy & Res Ctr, Inst Drug Dev, San Antonio, TX 78285 USA

[2] Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol, San Antonio, TX 78285 USA

来源：

SEMINARS IN ONCOLOGY | 2006年 / 33卷 / 04期

关键词：

D O I：

10.1053/j.seminoncol.2006.04.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The targeting of anti-apoptotic members of the Bcl-2 family of proteins, especially Bcl-2, is the focus of efforts to modulate the intrinsic pathway of apoptosis and effect tumor death. Current understanding of the role of Bcl-2 family proteins and strategies and recent developments in drug inhibitors of these proteins, particularly antisense oligonucleotides and targeted small molecules, are reviewed. © 2006 Elsevier Inc. All rights reserved.

引用

页码：449 / 456

页数：8

共 98 条

[1]

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML):: evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides [J].

Aichberger, KJ ;

Mayerhofer, M ;

Krauth, MT ;

Skvara, H ;

Florian, S ;

Sonneck, K ;

Akgul, C ;

Derdak, S ;

Pickl, WF ;

Wacheck, V ;

Selzer, E ;

Monia, BP ;

Moriggl, R ;

Valent, P ;

Sillaber, C .

BLOOD, 2005, 105 (08) :3303-3311

[2]

Allal AS, 2003, CLIN CANCER RES, V9, P6489

[3]

Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients [J].

Badros, A ;

Goloubeva, O ;

Rapoport, AP ;

Ratterree, B ;

Gahres, N ;

Meisenberg, B ;

Takebe, N ;

Heyman, M ;

Zwiebel, J ;

Streicher, H ;

Gocke, CD ;

Tomic, D ;

Flaws, JA ;

Zhang, B ;

Fenton, RG .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) :4089-4099

[4]

Bairey O, 1999, CLIN CANCER RES, V5, P2860

[5]

CLONING THE CHROMOSOMAL BREAKPOINT OF T(14-18) HUMAN LYMPHOMAS - CLUSTERING AROUND JH ON CHROMOSOME-14 AND NEAR A TRANSCRIPTIONAL UNIT ON 18 [J].

BAKHSHI, A ;

JENSEN, JP ;

GOLDMAN, P ;

WRIGHT, JJ ;

MCBRIDE, OW ;

EPSTEIN, AL ;

KORSMEYER, SJ .

CELL, 1985, 41 (03) :899-906

[6]

MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].

Bartel, David P. .

CELL, 2007, 131 (04) :11-29

[7]

Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells:: role of wild-type p53 and Bcl-XL [J].

Bauer, JA ;

Trask, DK ;

Kumar, B ;

Los, G ;

Castro, J ;

Lee, JSJ ;

Chen, JY ;

Wang, SM ;

Bradford, CR ;

Carey, TE .

MOLECULAR CANCER THERAPEUTICS, 2005, 4 (07) :1096-1104

[8]

Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-XL [J].

Becattini, B ;

Kitada, S ;

Leone, M ;

Monosov, E ;

Chandler, S ;

Zhai, DY ;

Kipps, TJ ;

Reed, JC ;

Pellecchia, M .

CHEMISTRY & BIOLOGY, 2004, 11 (03) :389-395

[9]

BENZ CC, 1990, MOL PHARMACOL, V37, P840

[10]

Role for a bidentate ribonuclease in the initiation step of RNA interference [J].

Bernstein, E ;

Caudy, AA ;

Hammond, SM ;

Hannon, GJ .

NATURE, 2001, 409 (6818) :363-366

← 1 2 3 4 5 6 7 8 9 10 →